MedTrace Logo

Glycemic Control on Coronary Inflammation Evaluated by FAI in ACS

NCT05590858 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 309

Last updated 2022-10-21

No results posted yet for this study

Summary

This study aimed to clarify the relationship between blood glucose control and the FAI based pericoronary inflammation in low-risk ACS patients with or without diabetes. The results of this study are expected to provide evidence that quantitative assessment of pericoronary FAI helps monitor the local inflammatory activation in diabetic patients with poor glycemic control, therefore, pericoronary FAI evaluation, as a noninvasive imaging biomarker, plays an important role in early detecting coronary atherosclerosis risk in diabetes and allow timely providing appropriate risk reduction strategies in patients at high risk for future cardiovascular events.

Conditions

  • Inflammation Vascular

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Song Ding, Doctor · RenJi Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-31
Completion
2022-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590858 on ClinicalTrials.gov